Safety and 1‐Year Outcomes After Transplanting Hearts From SARS‐CoV‐2 Positive Donors: Insights From an International Analysis
Using selected SARS-CoV-2-positive hearts for transplant appears safe with no differences in 1-year survival, no evidence of viral transmission or SARS-CoV-2-related adverse cardiovascular events.
Authors
- Angelika Costard‐Jäckle (ORCID: https://orcid.org/0000-0003-1464-239X)
- Kiran Kaur Khush (ORCID: https://orcid.org/0000-0001-9697-5926)
- Henrik Fox (ORCID: https://orcid.org/0000-0002-2187-8715)
- Jan Fritz Gummert (ORCID: https://orcid.org/0000-0002-6956-9110)
- B. Wayda
- Yasuhiro Shudo (ORCID: https://orcid.org/0000-0002-4545-1273)
- Josephine Wadewitz
- Michiel Morshuis (ORCID: https://orcid.org/0000-0002-6178-5791)
- Axel O Rahmel (ORCID: https://orcid.org/0000-0003-1701-4356)
- Y. Joseph Woo (ORCID: https://orcid.org/0000-0002-2506-492X)
- René Schramm (ORCID: https://orcid.org/0000-0001-5803-3575)
- Jeffrey J. Teuteberg (ORCID: https://orcid.org/0000-0002-8342-3222)
- Rayan Cheaban (ORCID: https://orcid.org/0009-0006-3272-0426)
- William Hiesinger
- S. Guenther (ORCID: https://orcid.org/0009-0003-2968-9702)
Institutions
- Heart and Diabetes Center North Rhine-Westphalia (DE)
- Association of Organ Procurement Organizations (US)
- German Organ Transplantation Foundation (DE)
- Ruhr University Bochum (DE)
- Stanford University (US)
Publication Details
- Journal
- Immunity Inflammation and Disease
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1002/iid3.70252
- Primary Topic
- Mechanical Circulatory Support Devices
- Type
- article
- Field-Weighted Citation Impact
- 0.00